Technical Analysis for AQST - Aquestive Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 1.20% | |
| Wide Bands | Range Expansion | 1.20% | |
| NR7 | Range Contraction | 1.83% | |
| Narrow Range Bar | Range Contraction | 1.83% | |
| Stochastic Reached Oversold | Weakness | 1.83% | |
| Inside Day | Range Contraction | 1.83% | |
| Wide Bands | Range Expansion | 1.83% | |
| Oversold Stochastic | Weakness | 1.83% | |
| Stochastic Buy Signal | Bullish | -0.35% | |
| Inside Day | Range Contraction | -0.35% |
| Alert | Time |
|---|---|
| Rose Above 10 DMA | 8 minutes ago |
| 10 DMA Resistance | 21 minutes ago |
| Up 2% | 21 minutes ago |
| Up 1% | 21 minutes ago |
| Rose Above Previous Day's High | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 06/20/2024
Aquestive Therapeutics, Inc. Description
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Disease Drugs Psychoactive Drugs Opioids Epilepsy Amyotrophic Lateral Sclerosis Chloroarenes Seizure Gabaa Receptor Positive Allosteric Modulators Neuroendocrine Tumors Neuroendocrine Tumor Parkinson’s Disease Anaphylaxis Riluzole
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.23 |
| 52 Week Low | 1.2514 |
| Average Volume | 2,962,510 |
| 200-Day Moving Average | 2.57 |
| 50-Day Moving Average | 4.17 |
| 20-Day Moving Average | 3.62 |
| 10-Day Moving Average | 3.28 |
| Average True Range | 0.33 |
| RSI (14) | 40.83 |
| ADX | 19.17 |
| +DI | 17.40 |
| -DI | 24.26 |
| Chandelier Exit (Long, 3 ATRs) | 3.56 |
| Chandelier Exit (Short, 3 ATRs) | 3.89 |
| Upper Bollinger Bands | 4.50 |
| Lower Bollinger Band | 2.74 |
| Percent B (%b) | 0.27 |
| BandWidth | 48.62 |
| MACD Line | -0.24 |
| MACD Signal Line | -0.22 |
| MACD Histogram | -0.0256 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.43 | ||||
| Resistance 3 (R3) | 3.44 | 3.39 | 3.40 | ||
| Resistance 2 (R2) | 3.39 | 3.33 | 3.38 | 3.38 | |
| Resistance 1 (R1) | 3.30 | 3.30 | 3.35 | 3.29 | 3.37 |
| Pivot Point | 3.25 | 3.25 | 3.27 | 3.24 | 3.25 |
| Support 1 (S1) | 3.16 | 3.19 | 3.21 | 3.15 | 3.07 |
| Support 2 (S2) | 3.11 | 3.16 | 3.10 | 3.06 | |
| Support 3 (S3) | 3.02 | 3.11 | 3.05 | ||
| Support 4 (S4) | 3.01 |
